|By PR Newswire||
|February 12, 2014 09:43 AM EST||
NEW YORK, Feb. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
"PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012" report provides an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing and Collaboration & Partnerships.
The report also provides understanding on the regional differences in the deal making activity to that of the global trends and key trends are outlined with insight on drivers such as regulatory policy, macro-economic and industry factors as well as market access challenges. Case studies including the top five deals in value among Mergers & Acquisition, Licensing and Collaboration & Partnerships are strategically analyzed to provide comprehensive understanding on areas such as structure and status of the deal vis a vis the overall corporate strategy.
Key Questions Answered
- How are the main deal categories faring among top countries in the Latin America region over the past five years?
- What are the primary reasons for increased activity in strategic deals by leading pharmaceutical companies in LATAM region?
- What are the key trends, and strategies involved in M&As, licensing deals, and collaboration agreements entered into by leading pharmaceutical and healthcare companies in the Latin American region?
- What strategies are the most successful companies pursuing to gain and maintain their market leading position?
- Which are the key companies that are potential targets of acquisitions?
- Report provides in-depth understanding of the key pharmaceutical and healthcare deals that took place in the LATAM region during the past five years. Furthermore, key deals are discussed from a domestic and global point of view.
- Current regulatory framework in various markets in LATAM including recent and/or ongoing developments that are expected to impact or influencing the industry are discussed. In-depth commentary on four countries in the region are included.
- Highly Insightful analyses on the deal making terms, strategic implications and synergies of recent deals activity in the LATAM pharmaceutical industry.
- Collaboration & Acquisition Strategies: Exhaustive discussion on the strategic implications and synergies of recent M&A and partnering activities. Case Studies of five deals are included in each deal category.
- Expert Insights on the corporate strategies of various drug companies seeking a competitive advantage in the pharmaceutical market place.
- Five major regional companies are profiled providing an in-depth analysis on their individual deal making strategies.
- Number of Case Studies on top deal making activities shedding light on rationale and strategy. Potential targets for acquisitions in the region are also identified.
Reasons to buy
- Understand the primary drivers behind major deal initiatives in the LATAM region.
- Analyze the structure of the deals and gain insight on the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
- Identify rationale behind potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships in the Asia Pacific region.
- Use this information as an independent source for your due diligence and transaction strategy.
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Report Scope 14
2.1.1 Key Questions Answered 14
2.1.2 Key Benefits 15
2.1.3 Upcoming Related Reports 15
3 Historical Dealmaking Trends 16
3.1 Overview 16
3.2 Leading Deal Drivers 17
3.2.1 Dampening Global Pharmaceutical Markets 17
3.2.2 Intellectual Property Issues and Rising Competition 18
3.2.3 Universal Healthcare Access, Primary Healthcare, and Health Insurance 19
3.2.4 Increasing Consolidation 20
3.3 Overall Deals in Review 21
3.3.1 Review by Deal Type 21
4 Regional Country Profiles 28
4.1 Brazil 28
4.1.1 Overview 28
4.1.2 Top Deals by Value and Volume 29
4.1.3 Market Dynamics 31
4.2 Mexico 34
4.2.1 Overview 34
4.2.2 Top Deals by Value and Volume 35
4.2.3 Market Dynamics 37
4.3 Argentina 41
4.3.1 Overview 41
4.3.2 Top Deals by Value and Volume 42
4.3.3 Market Dynamics 44
4.4 Venezuela 48
4.4.1 Overview 48
4.4.2 Top Deals by Value and Volume 49
4.4.3 Market Dynamics 51
5 Mergers and Acquisitions 55
5.1 Overview 55
5.2 Case Studies 57
5.2.1 UnitedHealth Group Acquires Amil Participações 57
5.2.2 Hypermarcas Acquires Mantecorp Indústria Química e Farmacêutica 59
5.2.3 Hypermarcas Acquires Laboratório Neo Química 60
5.2.4 Acquisition of Lafrancol (Colombia) by Recalcine (Chile) 61
5.2.5 Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
6 Licensing Agreements 64
6.1 Overview 64
6.2 Case Studies 66
6.2.1 FBM Indústria Farmacêutica (FBM Farma) Enters into Licensing Agreement with Ampio Pharmaceuticals 66
6.2.2 FAES Farma and Pfizer Expand Bilastine License Agreement 67
6.2.3 CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
6.2.4 Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
6.2.5 Oxford Nutrascience Enters into Licensing Agreement with Aché Laboratórios 71
7 Collaborations and Partnerships 73
7.1 Overview 73
7.2 Case Studies 75
7.2.1 Pfizer Enters into an Agreement with Laboratório Teuto Brasileiro 75
7.2.2 Avesthagen Forms a Joint Venture with Uxmal 77
7.2.3 Baxter International Enters into Agreement with Hemobras for Recombinant Factor VIII (rFVIII) Hemophilia Treatment 78
7.2.4 Cristalia, Biolab, Eurofarma, and Libbs Enter into Joint Venture for Biological Medicines 80
7.2.5 Aché , Uniao Química Farmacêutica, Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
8 Deal Strategy of Major LATAM Companies 83
8.1 Amil Participações S.A. 83
8.1.1 Recent Deals: M&As, Licensing, and Partnerships 83
8.1.2 Overall Deal Strategy 84
8.2 Hypermarcas 85
8.2.1 Recent Deals: M&As, Licensing, and Partnerships 85
8.2.2 Overall Deals Strategy 86
8.3 Grupo Casa Saba 87
8.3.1 Recent Deals: M&As, Licensing, and Partnerships 87
8.3.2 Overall Deals Strategy 87
8.4 Genomma Lab Internacional 88
8.4.1 Recent Deals: M&As, Licensing, and Partnerships 88
8.4.2 Overall Deals Strategy 88
8.5 CFR Pharmaceuticals 89
8.5.1 Recent Deals: M&As, Licensing, and Partnerships 89
8.5.2 Overall Deals Strategy 90
9 Future Outlook 91
9.1 Overview 91
9.2 Deal-Making Trends 91
9.2.1 Mergers and Acquisitions 91
9.2.2 Licensing and Partnership Deals to Rise in Quest for Portfolio and Pipeline Growth 93
9.2.3 Market Access Challenges will Impact Deal Activity 93
10 Appendix 95
10.1 Bibliography 95
10.2 Abbreviations 97
10.3 About the Author 100
10.3.1 Industry Analyst 100
10.4 Director of Healthcare Industry Dynamics 100
10.5 Global Head of Healthcare 101
10.6 About the Industry Dynamics Team 101
10.7 About GlobalData 101
10.8 Disclaimer 102
1.1 List of Tables
Table 1: Overview of Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Brazil, 2008-2012 29
Table 2: Market Share Split of Pharma Firms in Brazil 33
Table 3: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Mexico, 2008-2012 35
Table 4: Pharmaceutical Market, Mexico, Forecast ($bn), 2011-2020 38
Table 5: Top 10 Pharma Firms in Mexico Revenue-Wise 39
Table 6: Top Healthcare Distribution Firms in Mexico Revenue-Wise 40
Table 7: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Argentina, 2008-2012 42
Table 8: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Table 9: Top 10 Pharma Firms in Argentina, Revenue-Wise 46
Table 10: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Venezuela, 2008-2012 49
Table 11: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Table 12: Top 10 M&A Deals by Value, LATAM Region, 2008-2012 56
Table 13: UnitedHealth Acquires Amil Participações 57
Table 14: Hypermarcas Acquires Mantecorp 59
Table 15: Hypermarcas Acquires Laboratório Neo Química Comércio e Indústria 60
Table 16: Recalcine Acquires Lafrancol 61
Table 17: Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
Table 18: Major Licensing Deals, LATAM Region, 2008-2012 64
Table 19: FBM Farma Indústria Farmacêutica Licenses Zertane from Ampio Pharmaceuticals 66
Table 20: Pfizer and Faes Farma in Licensing Deal for Bilastine 67
Table 21: CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
Table 22: Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
Table 23: Oxford Nutrascience Enters into Licensing Agreement with Ache Laboratórios 71
Table 24: Top 10 Collaboration and Partnership Deals in the LATAM Region, 2008-2012 74
Table 25: Pfizer Enters Into An Agreement With Laboratório Teuto Brasileiro 75
Table 26: Avesthagen Enters into Agreement with Uxmal 77
Table 27: Baxter International Enters Into Agreement With Hemobras 78
Table 28: Cristalia, Biolab, Eurofarma and Libbs Enter into Joint Venture 80
Table 29: Aché , Uniao Química Farmacêutica , Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
Table 30: Amil Participações ' Recent Deals Activity 83
Table 31: Hypermarcas' Recent Deals Activity 85
Table 32: Grupo Casa Saba's Recent Deals Activity 87
Table 33: Genomma Lab Internacional's Recent Deals Activity 88
Table 34: CFR Pharmaceuticals' Recent Deals Activity 89
List of Figures
Figure 1: Foreign Direct Investment Flow, LATAM Region, 2011-2012 17
Figure 2: Research and Development Spending of PhRMA Members, 2005-2012 18
Figure 3: Trend in M&A Deal Volume, LATAM Region, 2008-2012 22
Figure 4: Trend in M&A Deal Values, LATAM Region, 2008-2012 23
Figure 5: Volume of Licensing Deals, LATAM Region, 2008-2012 24
Figure 6: Trend in Licensing Deal Values, LATAM Region, 2008-2012 25
Figure 7: Trend in Collaboration and Partnership Deal Volumes, LATAM Region, 2009-2012 26
Figure 8: Trend in Collaboration and Partnership Deal Values, LATAM Region, 2009-2012 27
Figure 9: Trends in Deal Volume in Brazil, 2008-2012 30
Figure 10: Volume of Deal Types in Brazil, 2008-2012 31
Figure 11: Pharmaceutical Market, Brazil, Revenue ($bn), Forecast, 2013-2020 32
Figure 12: Trends in Deal Volume in Mexico, 2008-2012 36
Figure 13: Volume of Deal Types in Mexico, 2008-2012 37
Figure 14: Trend in Market Forecast in Mexico, 2011-2020 38
Figure 15: Trends in Deal Volume in Argentina, 2008-2012 43
Figure 16: Volume of Deal Types in Argentina, 2008-2012 44
Figure 17: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Figure 18: Trends in Deal Volume in Venezuela, 2009-2012 50
Figure 19: Trends in Volume of Deal Types in Venezuela, 2009-2012 50
Figure 20: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Figure 21: Number of M&A Deals in Major Countries, LATAM Region, 2008-2012 57
Figure 22: Split in Volume of Licensing Deals among Drug Development Phases, LATAM Region, 2008-2012 65
To order this report: PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
Contact Clare: [email protected]
Intl: +1 339-368-6001
Advances in technology and ubiquitous connectivity have made the utilization of a dispersed workforce more common. Whether that remote team is located across the street or country, management styles/ approaches will have to be adjusted to accommodate this new dynamic. In his session at 17th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., focused on the challenges of managing remote teams, providing real-world examples that demonstrate what works and what do...
Feb. 11, 2016 07:00 AM EST Reads: 302
Eighty percent of a data scientist’s time is spent gathering and cleaning up data, and 80% of all data is unstructured and almost never analyzed. Cognitive computing, in combination with Big Data, is changing the equation by creating data reservoirs and using natural language processing to enable analysis of unstructured data sources. This is impacting every aspect of the analytics profession from how data is mined (and by whom) to how it is delivered. This is not some futuristic vision: it's ha...
Feb. 11, 2016 06:45 AM EST Reads: 441
Silver Spring Networks, Inc. (NYSE: SSNI) extended its Internet of Things technology platform with performance enhancements to Gen5 – its fifth generation critical infrastructure networking platform. Already delivering nearly 23 million devices on five continents as one of the leading networking providers in the market, Silver Spring announced it is doubling the maximum speed of its Gen5 network to up to 2.4 Mbps, increasing computational performance by 10x, supporting simultaneous mesh communic...
Feb. 11, 2016 05:00 AM EST
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, will discuss using predictive analytics to ...
Feb. 11, 2016 02:45 AM EST Reads: 395
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, will discuss how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved effi...
Feb. 11, 2016 02:30 AM EST Reads: 253
The cloud promises new levels of agility and cost-savings for Big Data, data warehousing and analytics. But it’s challenging to understand all the options – from IaaS and PaaS to newer services like HaaS (Hadoop as a Service) and BDaaS (Big Data as a Service). In her session at @BigDataExpo at @ThingsExpo, Hannah Smalltree, a director at Cazena, will provide an educational overview of emerging “as-a-service” options for Big Data in the cloud. This is critical background for IT and data profes...
Feb. 11, 2016 01:15 AM EST Reads: 209
Father business cycles and digital consumers are forcing enterprises to respond faster to customer needs and competitive demands. Successful integration of DevOps and Agile development will be key for business success in today’s digital economy. In his session at DevOps Summit, Pradeep Prabhu, Co-Founder & CEO of Cloudmunch, covered the critical practices that enterprises should consider to seamlessly integrate Agile and DevOps processes, barriers to implementing this in the enterprise, and pr...
Feb. 11, 2016 01:00 AM EST Reads: 407
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
Feb. 11, 2016 01:00 AM EST Reads: 224
Sensors and effectors of IoT are solving problems in new ways, but small businesses have been slow to join the quantified world. They’ll need information from IoT using applications as varied as the businesses themselves. In his session at @ThingsExpo, Roger Meike, Distinguished Engineer, Director of Technology Innovation at Intuit, showed how IoT manufacturers can use open standards, public APIs and custom apps to enable the Quantified Small Business. He used a Raspberry Pi to connect sensors...
Feb. 11, 2016 12:45 AM EST Reads: 221
The principles behind DevOps are not new - for decades people have been automating system administration and decreasing the time to deploy apps and perform other management tasks. However, only recently did we see the tools and the will necessary to share the benefits and power of automation with a wider circle of people. In his session at DevOps Summit, Bernard Sanders, Chief Technology Officer at CloudBolt Software, explored the latest tools including Puppet, Chef, Docker, and CMPs needed to...
Feb. 11, 2016 12:30 AM EST Reads: 329
Data-as-a-Service is the complete package for the transformation of raw data into meaningful data assets and the delivery of those data assets. In her session at 18th Cloud Expo, Lakshmi Randall, an industry expert, analyst and strategist, will address: What is DaaS (Data-as-a-Service)? Challenges addressed by DaaS Vendors that are enabling DaaS Architecture options for DaaS
Feb. 10, 2016 11:45 PM EST Reads: 352
One of the bewildering things about DevOps is integrating the massive toolchain including the dozens of new tools that seem to crop up every year. Part of DevOps is Continuous Delivery and having a complex toolchain can add additional integration and setup to your developer environment. In his session at @DevOpsSummit at 18th Cloud Expo, Miko Matsumura, Chief Marketing Officer of Gradle Inc., will discuss which tools to use in a developer stack, how to provision the toolchain to minimize onboa...
Feb. 10, 2016 11:45 PM EST Reads: 113
DevOps is not just last year’s buzzword. Companies with DevOps practices are 2.5x more likely to exceed profitability, market share, and productivity goals. But how do you enable high performance? What can you do right now to start? Find out from DevOps experts including Gene Kim, co-author of "The Phoenix Project," and the Dynatrace Center of Excellence.
Feb. 10, 2016 09:15 PM EST
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Avere delivers a more modern architectural approach to storage that doesn’t require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbuilding of data centers ...
Feb. 10, 2016 09:00 PM EST
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
Feb. 10, 2016 04:00 PM EST Reads: 163